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A , , . , oped in recent years (9, 10) . In particular, enzyme Since the introduction of the radioimmunoassäy by immunoassays (11 -16) have proved to be suitable Berson & Yalow nearly three decades ago (l, 2), this alternatives to radioimmunoassays. The various ways technique has become a widely used tool in medical in which enzymes have been employed, either directly research and routine diagnosis. It is used for deter-or indirectly äs immunoassays labels, have been dismining and quantifying antigens such äs peptide and cussed in detail elsewhere (4, 17) . Enzyme labels most non-peptide hormones, drugs, enzymes, virüses, bac-commonly used in heterogenous enzyme immunoasterial and tumour constituents, and other organic says are perpxidases, 2 ) alkaline phosphatase and ß-substances of biological and environmental interest />-galactosidase. For homogeneous enzyme immuno-(2-6). Radioimmunoassays are relatively simple to assays, lysozyme, glucose-6-phosphate dehydrogehandle, and have a remarkably Wgh specificity and nase and malate dehydrogenase are most frequently sensitivity (4, 5) . Disadavantages are the contact with used äs enzyme labels (17) . These enzymes are very radioactive materiäl, the often short shelf-life of the effective catalysts, and their Substrates are suitable tracers, and the instability (radiolysis) of labelled for spectrophotometric determination (17) . A single antigens (7, 8 cules of Substrate into product per minute, but for some enzymes this figure can be s high s l O 6 -l O 7 (17) . Hence analytes can be detected in enzyme immunosassays down to femtomol levels.
Our aim was the development of a new type of enzyme Substrate based on luciferin derivatives, which are highly sensitive in the test Systems. These new Substrates can be used for unmodified enzymes and for enzyme conjugates, and applied in enzymatic test Systems and in enzyme immunoassays, respectively. Briefly, the release of D-luciferin (Photinus pyralis) from ZMuciferin conjugates is quantified by a luminometric detection System (25), allowing a determination of antigen concentrations down to 5 fg/1.
Materials and Methods
Synthetic ZMuciferin (Photinus pyralis), /?-nitrophenyl acetate, /7-nitrophenyl phosphate, p-nitrophenyl sulphate, hippuryl-Lphenylalanine, hipp ryl-L-arginine, N,N'-dicyclohexylcarbodiimide, l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, carboxylic esterase (porcine liver; 100 U/mg), carboxypeptidases A (bovine pancreas; 50 U/mg) and B (bovine pancreas; 175 U/mg), arylsulphatase (Helix pomatia; 400-600 U/mg) and alkaline phosphatase (bovine kidney; 200-400 U/mg; 25 °C) were purchased from Sigma, M nchen, FRG. 12 mg (30 μιηοΐ) of £Muciferm-N-hydroxysucciiuniide ester were dissolved in 0.3 ml dioxan and added to 0.2 ml L-arginine solution (0.6 mol/1, pH 7.5). The pH was adjusted to pH 6 by adding 2 mol/1 NaOH, and the mixture was incubated in the dark at 20 °C for 2 h. The reaction mixture was dried in a rotary evaporator. The dry residue was dissolved in 0.5 mol/1 ammonia and further purified by HPLC systein II.
Yield: 4.81 mg (37% of theory).
D-luciferin-O-sulphate (M T : 360.39)
20 mg (71 μπιοί) /Muciferin was dissolved in 0.6 rril dry pyridine and added to 16mg (100 μπιοί) of SO 3 /pyridme-coniplex. The reaction mixture was incubated at 20 °C in the dark for 2 h, dried in a rotary evaporator, dissolved in a smail volume of 0.5 mol/1 ammonia, and further purified by HPLC System III. Yield: 10.2 mg (36% of theory).
D-ludferin-O-phosphate (M T : 359.39)
50 mg (0.18 mmol) D-luciferin and 350 mg magnesium oxide were suspended in 3 ml water and cooled to 0 °C. Thereafter, 92 mg (0.6 mmol) of phosphorus oxytrichloride in l ml carbon tetrachloride were added dropwise to this Suspension. The reaction mixture was kept at 20 °C for 30 min, filtered and neutralized with acetic acid. After evaporation in vacuo, Dluciferin-O-phosphate was purified by HPLC systern III.
Yield: 21.5 mg (29% of theory).
Spectrometry
Ultraviolet spectra were measured at room temperature using a Zeiss PMQ 3 spectrophotorneter.
Fluorescence spectra were taken with a Hitachi fluorimeter 650-40 at room temperature.
Chromatography
Amino acid analyses were performed with a Biotronic amino acid analyser after hydrolysis of samples in 6 mol/1 HC1 for 24 hat 110 °C.
Thin layer chromatography was performed using the following Separation Systems: 
0.01 U) were incubated for 5 min. Then 0.05 ml substrate solution was added, and thc decrease in relative fluorescence units measurcd.
Precisely quantified luciferin derivatives and luciferin Solutions were used s calibration Standards for the fluorescence measurements. k^ values were calculated s described in 1. c. (27) .
Results and Discussion
The structure of luciferin, a complex heterocyclic chemical compound was elucidated in 1963 by White et al. (30) . Luciferin is very stable in solution at neutral pH, whereas in acid solution (pH below 2) a rapid degradation to Z)-eysteine and a benzthiazole derivative occurs. In alkaline solution luciferin is oxidized to dehydroluciferin which is a potent inhibitor of firefly luciferase (31) . For these reasons synthesis strategies had to be developed which lead to the expected luciferin derivatives, but do not destroy luciferin during synthesis. Luciferin derivatives (fig. 1) were synthesized s described in Materials and Methods. Luciferin methyl ester was synthesized s described by White et al. (l 8) using diazomethane. The chemical reaction proceeded problem-free, and the byproducts formed (nitrogen and methanol) could be easily removed. Remaining traces of unreacted luciferin were removed by silica gel chromatography. Thus a luciferin methyl ester preparation free of luciferin was obtained in 69% yield.
Luciferyl-L-phenylalanine and luciferyl-L-N a -arginine were synthesized via luciferin-N-hydroxysuccinimide. Luciferin-N-hydroxysuccinimide was prepared by reacting luciferin with N-hydroxysuccinimide in the precence of Ν,Ν'-dicyclohexylcarbodiimide. Synthesis of luciferyl-L-phenylalanine proceeded without Problems in relative high yield (63%). Synthesis of luciferyl-L-N a -arginine is more difficult to perform because of the presence of the reactive guanido group. Using slightly acid conditions (pH 6; (31)), luciferyl-L-N a -arginine could be synthesized in acceptable yield (37%).
Luciferin-O-sulphate was prepared by reacting luciferin with SO 3 /pyridine complex (32) in the dark. The relatively high selectivity of the reagent (only phenolic OH-groups are attacked; (32)) lead to the expected product in 36% yield.
In the preparation of luciferin-O-phosphate by phosphorus oxytrichloride in the dark and 0 °C, only a relatively low yield (29%) of luciferin-O-phosphate was obtained, because of the relative agressive reaction conditions. All synthesized Iuciferin derivatives were purified by high performance liquid chromätography (see fig. 1 ). Because of the high sensitivity of the luminoinetric assay (24) in which traces of Iuciferin would iiiterfere, all preparations of Iuciferin derivatives had to be free of Iuciferin. This was verified by thin layer chromatography (two Systems), by several HPLC Systems, and by the luminometric assay itself.
The identity of all Iuciferin derivatives was assessed by ultraviolet (tab. 1) and fluorescence spectroscopy (tab. 2 and fig. 1 ), and by mass spectrometry (tab. Furthermore, quantitative luciferin determinations were performed by the luminometric assay (tab. 4) and by fluörescence measurements. For this purpose, derivatives were incubated with the corresponding enzyme for a sufficiently long period (approx. 2 h) to release all ZMuciferin under optimal conditions. The amount of luciferin found by both methods was close to the calculäted vahies. In all these tests satisfactory results were obtained. Enzymatic studies clearly demonstrate that luciferin derivatives applied in the luminometric assay up to l mmol/1 cause no light enlission. In other words, the luciferin derivatives are not Substrates for firefly luciferase.
Depending on the concentrations of luciferin derivatives added to the luminometric assay (see t b. 5), luciferin derivatives can inhibit the light emitting reaction. The absence of this interference is essential *) protein concentration was given by manufacturer. **) protein concentration was determined according to Bradford (28) . Bovine serum albumin was used äs Standard. ***) enzyme activity was proven äs described in I.e. (19) (20) (21) (22) (23) .
for the sensitivity of the detection Systems of the immunoassays. Therefore, concentrations of luciferin derivatives were later used in the detection Systems which did not interfere in the luminometric assay (25) .
The most important point was whether the luciferin derivatives can be cleaved by enzymes and whether intact luciferin is indeed released by these reactions. As can be seen from the data in table 6, which have been obtained by following the hydrolytic reactions by the luminometric assay, luciferin derivatives can be cleaved by appropriated enzymes. Substitution of the hydroxyl group of the carboxyl group of luciferin by a methoxy group led to a compound which could be cleaved by carboxylic esterase. Substitution by a phenylalanine residue resulted in a Substrate for Carboxypeptidase A. Substitution by an arginine resi-• due in N(a) position gave a Substrate for Carboxypeptidase B. Formation of a sulphate with the hydroxyl group of luciferin led to a Substrate which was cleaved by arylsulphatase. Luciferin-O-phosphate was a subŝ trate for alkaline phosphatase. The Michaelis-Menten constants and V values deterniined for the luciferin Substrates and the respective enzymes were in a ränge typical for other Substrates of these enzymes.
Especially alkaline phosphatase showed a very high catalytic rate with the Substrate luciferin-O-phosphate. The sensitivity of the assay is about sixty-fold higher than with the usual Substrate /?-nitrophenyl phosphate.
Conclusion
In surnmary, the present luciferin derivatives fulfil all prerequisite conditions for their use in enzyme immunoassays with a bioluminescent detection system äs outlined in figure 3. Such assays are described in detail in the accompanying paper (25) .
-OR -OH -OH Fig. 3 . Scheine of the bioluminometric detection System for enzyme-labelled antibodies. a) liberation of luciferin from luciferin derivatives substituted at the carboxyl group; b) release of luciferin from luciferin derivatives substituted at the hydroxyl group.
